These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 19616449)

  • 1. The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis.
    Engel D; Seijkens T; Poggi M; Sanati M; Thevissen L; Beckers L; Wijnands E; Lievens D; Lutgens E
    Semin Immunol; 2009 Oct; 21(5):308-12. PubMed ID: 19616449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD40 and its ligand in atherosclerosis.
    Lutgens E; Lievens D; Beckers L; Donners M; Daemen M
    Trends Cardiovasc Med; 2007 May; 17(4):118-23. PubMed ID: 17482093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis.
    Lievens D; Eijgelaar WJ; Biessen EA; Daemen MJ; Lutgens E
    Thromb Haemost; 2009 Aug; 102(2):206-14. PubMed ID: 19652870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD154 and its receptors in inflammatory vascular pathologies.
    Hassan GS; Merhi Y; Mourad WM
    Trends Immunol; 2009 Apr; 30(4):165-72. PubMed ID: 19282242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD40 and its crucial role as a member of the TNFR family.
    Vogel LA; Noelle RJ
    Semin Immunol; 1998 Dec; 10(6):435-42. PubMed ID: 9826576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells.
    Zirlik A; Bavendiek U; Libby P; MacFarlane L; Gerdes N; Jagielska J; Ernst S; Aikawa M; Nakano H; Tsitsikov E; Schönbeck U
    Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1101-7. PubMed ID: 17332487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD40/CD40L interaction induces Abeta production and increases gamma-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling.
    Volmar CH; Ait-Ghezala G; Frieling J; Weeks OI; Mullan MJ
    Exp Cell Res; 2009 Aug; 315(13):2265-74. PubMed ID: 19422822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD154-CD40 interactions are essential for thymus-dependent antibody production in zebrafish: insights into the origin of costimulatory pathway in helper T cell-regulated adaptive immunity in early vertebrates.
    Gong YF; Xiang LX; Shao JZ
    J Immunol; 2009 Jun; 182(12):7749-62. PubMed ID: 19494299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease.
    Rizvi M; Pathak D; Freedman JE; Chakrabarti S
    Trends Mol Med; 2008 Dec; 14(12):530-8. PubMed ID: 18977174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease.
    Howard LM; Miller SD
    Autoimmunity; 2004 Aug; 37(5):411-8. PubMed ID: 15621565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CD40/CD40 ligand system: linking inflammation with atherothrombosis.
    Antoniades C; Bakogiannis C; Tousoulis D; Antonopoulos AS; Stefanadis C
    J Am Coll Cardiol; 2009 Aug; 54(8):669-77. PubMed ID: 19679244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD40/CD154 system and pro-inflammatory cytokines in young healthy male smokers without additional risk factors for atherosclerosis.
    Garlichs CD; Cicha I; Raaz D; Meyer L; Stumpf C; Klinghammer L; Yilmaz A; Daniel WG
    Inflamm Res; 2009 Jun; 58(6):306-11. PubMed ID: 19190856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway.
    Toubi E; Shoenfeld Y
    Autoimmunity; 2004; 37(6-7):457-64. PubMed ID: 15621572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD40/CD40L dyad in the inflammatory and immune responses in the central nervous system.
    Chen K; Huang J; Gong W; Zhang L; Yu P; Wang JM
    Cell Mol Immunol; 2006 Jun; 3(3):163-9. PubMed ID: 16893496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costimulatory molecule CD154 in systemic lupus erythematosus and rheumatoid arthritis. Therapeutic perspectives.
    Dejica DI; Manea EM
    Roum Arch Microbiol Immunol; 2006; 65(1-2):66-74. PubMed ID: 17877113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of CD40 ligand dysregulation in HIV-associated dysfunction of antigen-presenting cells.
    Chougnet C
    J Leukoc Biol; 2003 Nov; 74(5):702-9. PubMed ID: 12960257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Blockade of CD40/CD154 signal as a therapeutic strategy for autoimmune diseases].
    Kuwana M
    Nihon Rinsho Meneki Gakkai Kaishi; 2003 Oct; 26(5):259-66. PubMed ID: 14635399
    [No Abstract]   [Full Text] [Related]  

  • 18. The CD40-CD40 ligand system: a potential therapeutic target in atherosclerosis.
    Phipps RP; Koumas L; Leung E; Reddy SY; Blieden T; Kaufman J
    Curr Opin Investig Drugs; 2001 Jun; 2(6):773-7. PubMed ID: 11572655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CD40/CD40L system: a new therapeutic target for disease.
    Zhang B; Wu T; Chen M; Zhou Y; Yi D; Guo R
    Immunol Lett; 2013 Jun; 153(1-2):58-61. PubMed ID: 23892087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis.
    Suttles J; Stout RD
    Semin Immunol; 2009 Oct; 21(5):257-64. PubMed ID: 19540774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.